Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers ...
The company's shares rose as investors breathed a sigh of relief on strong sales growth and guidance, despite ongoing ...
Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...
Novo Nordisk reported turnover from obesity treatments soared by 57 per cent to 65.1 billion Danish kroner last year, largely ...
Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...
Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback